Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR

International Journal of Cancer

Volumn 114, Issue 2, 2005, Pages 174-181

  Fromont, Gaëlle ^a,b   Chene, Laurent ^c   Vidaud, Michel ^d   Vallancien, Guy ^b   Mangin, Philippe ^a,e   Fournier, Georges ^a,f   Validire, Pierre ^b   Latil, Alain ^c   Cussenot, Olivier ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c Parc Scientifique de Luminy   (France)

^d Laboratoire des Sciences Vegetales   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Disease progression; Prostate cancer; Quantitative evaluation

Indexed keywords

ANDROGEN; GROWTH FACTOR; HEPSIN; SERINE PROTEINASE; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SCREENING; HORMONE DEPENDENCE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROIDOGENESIS;

ANDROGENS; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LYMPH NODE EXCISION; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 13244298245     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20704     Document Type: Article

References (48)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Stearn ME, McGarvey T. Biology of disease: prostate cancer: therapeutics, diagnostic and basic studies. Lab Invest 1992;67:540-52.
3. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J. Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
4. Chomezinsky P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 1987;162:156-9.
5. Altschul SF, Gish W, Miller W, Myers EW, Lipma D. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
6. Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med 2004;330:1814-6.
7. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancer: it is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61-73.
8. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanism of therapy resistance. Am J Pathol 2004;164:217-27.
9. Latil A, Bieche Y, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen, and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61:1919-26.
10. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessela RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer cells. Cancer Res 2001;61:3550-5.
11. Ito T, Tachibana M, Yamamoto S, Nakashima J, Murai M. Expression of estrogen receptor (alpha and beta) mRNA in human prostate cancer. Eur Urol 2001;40:557-63.
12. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T. Expression of ER alpha and ER beta in prostate cancer. Prostate 2003;55:180-6.
13. Chang WY, Prins GS. Estrogen receptor-beta: implication for the prostate gland. Prostate 1999;40:115-24.
14. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900-7.
15. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR. Protein and mRNA for the type 1 insulin-like growth factor receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-82.
16. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203-9.
17. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271-9.
18. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is upregulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
19. Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer; a comparison with mammary carcinoma. J Urol 2002;168:1412-4.
20. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammale TL, Isola JJ, Visakorpi T. Expression and gene copy analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002;160:339-45.
21. Agus DB, Akita RW, Fox WD. Targeting ligand-activated ErbB2 signalling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37.
22. Koivisto P, Visakorpi T, Rantala I, Isola J. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol 1997;183:51-6.
23. Bookstein R. Tumor suppressor genes in prostate cancer. In: Chung NW, Isaacs WB, Simons JW, eds. Prostate cancer: biology, genetics, and new therapeutics. Totowa, NJ: Humana, 2001. 61-93.
24. Latil A, Bieche Y, Pesche S, Volant A, Valeri A, Fournier G, Cussenot O, Lidereau R. Loss of heterozygosity at chromosome arm 13q and Rb1 status in human prostate cancer. Human Pathol 1999;30:809-15.
25. Meyer FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, Devere White R. Very frequent P53 mutations in metastatic prostate carcinoma and in matched primary tumours. Cancer 1998;83:2534-9.
26. Van Brussel JP, Van Steenbrugge GJ, Van Krimpen C. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001;165:130-5.
27. Willman JH, Holden JA. Immunostaining of DNA topoisomerase II alpha in benign, premalignant, and malignant lesions of the prostate. Prostate 2000;42:280-6.
28. Rauh-Adelmann C, Lau KM, Sabeti N, Long JP, Mok SC, Ho SM. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol Carcinog 2000;28:236-46.
29. Vissac C, Peffault De Latour M, Communal Y, Bignon YJ, Bernard-Gallon DJ. Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status. Clin Chim Acta 2002;320:101-10.
30. Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM, Kisiel W. Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 1998;79:876-7.
31. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-6.
32. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
33. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. Hepsin inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002;62:6812-6.
34. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389-98.
35. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bidendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC. Elevated expression of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-25.
36. 34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;1:230-5.
37. Xing N, Qian J, Bostwick D, Bergstrahl E, Young CY. Neuroendocrine cells in human prostate overexpress the anti-apoptosis protein survivin. Prostate 2001;48:7-15.
38. Abrahamsson PA. Neuroendocrine cells in tumor growth of the prostate. Endocr Relat Cancer 1999;6:503-19.
39. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000;31:406-14.
40. Shimoda J, Koh D, Kigure T, Harada T, Tsuchida S, Kudo K. Effect of bombesin and its antibody on human prostatic carcinoma cell lines. J Urol 1991;145:400-5.
41. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptor for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000;42:295-303.
42. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancer in humans. Am J Physiol 1999;276:655-65.
43. Glover SC, Tretiakova MS, Carroll RE, Benya RV. Increased frequency of gastrin-releasing peptide receptor gene mutations during colon adenocarcinoma progression. Mol Carcinog 2003;37:5-15.
44. Kallakury BV, Sheehan CE, Ross JS. Co-downregulation of cell adhesion proteins alpha and beta catenins, p120CTN, E-cadherin, and CD44 in prostatic carcinomas. Hum Pathol 2001;32:849-55.
45. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-33.
46. Chen Y, Wang J, Fraig MM. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001;61:4112-21.
47. Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate 2001;47:269-75.
48. Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, Sagalowsky AI, McConnel JD, Marston W, Leach FS. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 2002;94:690-9.